EXTENSIVE LIFE OY

Their core work

Extensive Life Oy is a Finnish private health company based in Tampere that participates in large-scale European health research consortia. Their work spans two distinct but related areas: community-based chronic disease prevention — specifically type 2 diabetes — and long-term outcomes research for children and adults born preterm. As a small company selected to join major multi-country Research and Innovation Actions, they contribute specialist health expertise alongside academic and clinical partners. The exact nature of their proprietary offering is not captured in available project data, but their consistent selection by large consortia suggests a well-defined niche capability.

What they specialise in

How they've shifted over time

In their early H2020 participation (Feel4Diabetes, starting 2014), the focus was on active public health intervention — designing and implementing programs to change environments and behaviours to prevent type 2 diabetes at the community level. Their later project (RECAP preterm, starting 2017) shifted toward retrospective and longitudinal outcomes research, following cohorts of preterm-born individuals over many years. This suggests a broadening from intervention design toward health outcomes measurement, though both areas remain firmly within population and preventive health.

They appear to be moving from active health intervention programs toward outcomes and longitudinal cohort research, which may signal growing expertise in health data analysis and long-term follow-up study design.

How they like to work

Extensive Life Oy participates exclusively as a consortium partner, never as a project coordinator, indicating a preference for contributing specialist expertise within larger research structures rather than leading them. Both projects were large RIA consortia, and their 28 unique partners across 16 countries from just two participations confirms they consistently join well-networked, multi-stakeholder international programs. This profile points to a reliable specialist contributor rather than a project initiator or consortium driver.

Despite only two projects, the company has accumulated 28 unique consortium partners across 16 countries, reflecting the large multi-partner structures of both RIA consortia they joined. No clear geographic concentration is evident beyond a broad European scope.

What sets them apart

As a small Finnish private company consistently selected by large European health research consortia, Extensive Life Oy brings something specific enough to earn its place alongside universities and clinical research institutes. Their combination of diabetes prevention and preterm outcomes work points to a focus on vulnerable populations and long-term health trajectories — a relatively specialised niche within public health. However, with no website and limited public data, their precise proprietary capability or technology offering cannot be confirmed from CORDIS data alone.

Highlights from their portfolio

• RECAP preterm
  Their largest project by EC funding (EUR 187,500), this pan-European cohort study tracking adults born preterm is a major long-term research effort with direct implications for neonatal care policy and adult chronic disease management.
• Feel4Diabetes
  Their earliest H2020 project, demonstrating roots in community-level diabetes prevention and environmental health intervention — a practically oriented complement to their later outcomes research work.